The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term moderate-to-severe pain in adults. It’s the first of a new class of analgesics to be approved in over 20 years,

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain.

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.

United States’ Food and Drug Administration landed on a major decision regarding the pain medication and the tendency for addiction due to opioid usage.As reported by Associated Press, on Thursday, the federal agency approved a

The FDA approves suzetrigine, a non-opioid pain medication, offering a safer alternative to opioids for pain management, reducing risks of addiction and euphoria.

On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid painkiller that could change the way doctors treat acute pain. The drug, developed by Vertex Pharmaceuticals,

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults.  “Today’s approval is

The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.

The FDA approved Vertex Pharmaceuticals' Journavx, a new non-opioid pain pill for short-term pain. While safer than opioids, studies show it's only modestly effective compared to opioid-acetaminophen combinations.